Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Balance at Dec. 31, 2023	$ 225,689		$ 535,468	$ 224	$ (310,003)
Balance, Shares at Dec. 31, 2023		51,445,862
Stock-based compensation expense	2,610		2,610
Net loss	(15,270)				(15,270)
Unrealized loss on investments	(319)			(319)
Foreign currency translation (loss) gain	(34)			(34)
Balance at Mar. 31, 2024	212,676		538,078	(129)	(325,273)
Balance, Shares at Mar. 31, 2024		51,445,862
Balance at Dec. 31, 2023	225,689		535,468	224	(310,003)
Balance, Shares at Dec. 31, 2023		51,445,862
Net loss	(35,709)
Foreign currency translation (loss) gain	(25)
Balance at Sep. 30, 2024	197,908		543,210	410	(345,712)
Balance, Shares at Sep. 30, 2024		51,749,504
Balance at Mar. 31, 2024	212,676		538,078	(129)	(325,273)
Balance, Shares at Mar. 31, 2024		51,445,862
Exercise of stock options and common stock issued under the 2020 ESPP	141		141
Exercise of stock options and common stock issued under the 2020 ESPP, Shares		76,263
Stock-based compensation expense	2,767		2,767
Net loss	(1,213)				(1,213)
Unrealized loss on investments	(61)			(61)
Foreign currency translation (loss) gain	5			5
Balance at Jun. 30, 2024	214,316		540,987	(185)	(326,486)
Balance, Shares at Jun. 30, 2024		51,522,125
Release of vested restricted stock units issued under the 2020 EIP		227,379
Stock-based compensation expense	2,224		2,224
Net loss	(19,226)				(19,226)
Unrealized loss on investments	591			591
Foreign currency translation (loss) gain	4			4
Balance at Sep. 30, 2024	197,908		543,210	410	(345,712)
Balance, Shares at Sep. 30, 2024		51,749,504
Balance at Dec. 31, 2024	176,080		544,653	139	(368,712)
Balance, Shares at Dec. 31, 2024		51,935,134
Exercise of stock options	10		10
Exercise of stock options, Shares		19,001
Stock-based compensation expense	1,508		1,508
Net loss	(17,436)				(17,436)
Unrealized loss on investments	(62)			(62)
Foreign currency translation (loss) gain	7			7
Balance at Mar. 31, 2025	160,107		546,171	84	(386,148)
Balance, Shares at Mar. 31, 2025		51,954,135
Balance at Dec. 31, 2024	$ 176,080		544,653	139	(368,712)
Balance, Shares at Dec. 31, 2024		51,935,134
Exercise of stock options, Shares	22,199
Net loss	$ (59,705)
Foreign currency translation (loss) gain	7
Balance at Sep. 30, 2025	120,999		549,325	91	(428,417)
Balance, Shares at Sep. 30, 2025		52,993,238
Balance at Mar. 31, 2025	160,107		546,171	84	(386,148)
Balance, Shares at Mar. 31, 2025		51,954,135
Exercise of stock options and common stock issued under ESPP and release of vested restricted stock units, Value	103		103
Exercise of stock options and common stock issued under ESPP and release of vested restricted stock units, Shares		1,039,103
Stock-based compensation expense	1,668		1,668
Net loss	(21,210)				(21,210)
Unrealized loss on investments	(61)			(61)
Foreign currency translation (loss) gain	(2)			(2)
Balance at Jun. 30, 2025	140,605		547,942	21	(407,358)
Balance, Shares at Jun. 30, 2025		52,993,238
Stock-based compensation expense	1,383		1,383
Net loss	(21,059)				(21,059)
Unrealized loss on investments	69			69
Foreign currency translation (loss) gain	1			1
Balance at Sep. 30, 2025	$ 120,999		$ 549,325	$ 91	$ (428,417)
Balance, Shares at Sep. 30, 2025		52,993,238

PMV Pharmaceuticals, Inc. 10-Q